Akademik Veri Yönetim Sistemi
VIRAL HEPATIT DERGISI-VIRAL HEPATITIS JOURNAL, cilt.20, sa.1, ss.23-27, 2014 (ESCI, TRDizin)
Objective: Perinatal transmission is one of the most common transmission routes of hepatitis B virus (HBV) disease. It is possible to prevent transmission with antiviral treatment performed in pregnant women with high viral load in adition to the passive and active immunization treatment performed in the infant. The aim of this study was to investigate the safety of antiviral treatment during pregnancy and its effects on the seroconvertion of Hepatitis B in pregnant and newborn. Materials and Methods: The effects of antiviral treatment (lamivudine, tenofovir, telbivudine) performed in 17 pregnant women who were admitted to the infectious disease outpatient clinic of our hospital between years 2011-2013 and who had chronic hepatitis B (CHB) and a high viral load on the mother andt the newborn were evaluated retrospectively. Results: Following 8-12 weeks of antiviral treatment, HBV-DNA levels were decreased to <= 10.000 IU/mL in the 11/17 (64.7%) patients, there were >2log10 (IU/mL) of reduction in average, liver enzymes were decreased in 15/17 (88.2%) patients. There were no observed drug side effects and complications in mother and newborn. Conclusion: After the antiviral therapy viral load decreased in HBsAg positive pregnant women and perinatal transmission is prevented, thus, this supported the aim of "obtaining HBV seroconversion only with immunization".